<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037411</url>
  </required_header>
  <id_info>
    <org_study_id>S2346</org_study_id>
    <nct_id>NCT03037411</nct_id>
  </id_info>
  <brief_title>A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries</brief_title>
  <acronym>REGAL</acronym>
  <official_title>A Real World Evaluation of the ELUVIA Drug Eluting Stent in All-Comers With Superficial Femoral Artery and Proximal Popliteal Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REGAL study is a European, prospective, multi-center Post-Market Clinical Follow-up
      (PMCF) trial providing additional data including health economics data to support the use of
      the ELUVIA stent in the treatment of lesions located in the femoropopliteal arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing
      additional data including health economics data to support the use of the ELUVIA stent in the
      treatment of lesions located in the femoropopliteal arteries.

      The objective of the study is to collect additional data including health economics data to
      support the use of the ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating
      Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health care costs</measure>
    <time_frame>Index Procedure, 1, 6, 12 and 24 months</time_frame>
    <description>Health care costs at index procedure and changes in health care costs from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Change in EQ-5D-5L™ from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Improvement</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Change in Walking Impairment Questionnaire (WIQ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Primary and Secondary Sustained Clinical Improvement</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Changes in Rutherford Classification from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hemodynamic Improvement</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Changes in in Ankle-Brachial Index (ABI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilization</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Changes in healthcare utilization over time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Technical success of the stenting procedure</measure>
    <time_frame>During stenting procedure</time_frame>
    <description>Technical success defined as delivery and deployment of the study stent to the target lesion to achieve residual angiographic stenosis no greater than 30% assessed visually</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural success of the stenting procedure</measure>
    <time_frame>within 24 hours of stenting procedure</time_frame>
    <description>Procedural success defined as technical success with no MAEs noted within 24 hours of the stenting procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Event and Major Adverse Event (MAE) rate</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Adverse Event rate and MAE rate, defined as all causes of death, target limb major amputation and/or Target Lesion Revascularization rate at each time point</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary patency</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Primary patency of target lesion assessed by duplex ultrasound as adjudicated by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven Target Lesion Revascularization (TLR) Rate</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Target Lesion Revascularization is defined as any surgical or percutaneous intervention to the target lesion(s) after the stenting procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven Target Vessel Revascularization (TVR) Rate</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Target Vessel Revascularization is defined as any surgical or percutaneous intervention to the target vessel after the stenting procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of Rutherford Classification</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Rutherford Classification:
0 Asymptomatic - Normal Treadmill /stress test
Mild claudication - Completes treadmill exercise; ankle pressure (AP) after exercise &lt;50mm Hg, but &gt;25 mm Hg less than BP
Moderate claudication - Between categories 1 and 3
Severe claudication - Cannot complete treadmill exercise and AP after exercise &lt;50 mm Hg
Ischemic rest pain - Resting AP &lt;40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); toe pressure (TP) &lt;30 mm Hg
Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal edema - Resting AP &lt;60 mm Hg, ankle or metatarsal (MT) PVR flat or barely pulsatile; TP &lt;40 mm Hg
Major tissue loss-extending above MT level - Same as Category 5</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">291</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Atherosclerosis</condition>
  <condition>Vascular Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>ELUVIA stent implantation</arm_group_label>
    <description>Peripheral stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripheral stenting</intervention_name>
    <description>stent implantation during the index procedure</description>
    <arm_group_label>ELUVIA stent implantation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Intended population for the REGAL study are 'real world'-patients with symptomatic
        de-novo, restenotic, or (re)occluded lesions in the native superficial femoral artery (SFA)
        and/or proximal popliteal artery with reference vessel diameter (RVD) ranging from 4.0-6.0
        mm, suitable for endovascular treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects age 18 and older

          2. Subject is willing and able to provide written consent before any study-specific test
             or procedure is performed and agrees to attend all follow-up visits

          3. De novo, restenotic or (re)occluded lesions in the native femoro-popliteal arteries,
             with reference vessel diameter (RVD) ranging from 4.0-6.0 mm, suitable for
             endovascular treatment

        Exclusion Criteria:

          1. Subject is pregnant or planning to become pregnant during the course of the study

          2. Life expectancy of less than 1 year (which is defined as documented life expectancy
             less than 12 months due to other medical co-morbid condition(s) that could limit the
             subject's ability to participate in the clinical follow-up, limit the subject's
             compliance with the standard of care follow-up, or impact the scientific integrity of
             the trial)

          3. Known allergy to the ELUVIA stent system or any of its components, concomitant
             medication, contrast agents (that cannot be medically managed)

          4. Subject enrolled in an investigational study that has not reached primary endpoint at
             the time of enrollment or that clinically interferes with the current study
             assessments (Note: studies requiring extended follow-up for products that were
             investigational, but have become commercially available since then are not considered
             investigational studies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Setacci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Le Scotte, Siena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL Genk</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart Tienen</name>
      <address>
        <city>Tienen</city>
        <state>Vlaams-Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble-Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Parly II</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Asti</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Azienda sanitaira ASL Roma 1</name>
      <address>
        <city>Roma</city>
        <zip>00193</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp . Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Ntra Sra. del Rosario</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Complejo Hosp Universitario (CHUO)</name>
      <address>
        <city>Ourense</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Montecelo (Pontevedra EOXI)</name>
      <address>
        <city>Pontevedra</city>
        <zip>30071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foundation for the Aragonese Healthcare Research Institute</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Superficial Femoral Artery (SFA)</keyword>
  <keyword>Proximal Popliteal Artery (PPA)</keyword>
  <keyword>Stenting</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Health Economics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

